ARCH Venture Partners brought in $2.975bn for its latest fund to give additional long-term investors a place at the table as the VC firm creates, builds and supports new early-stage biotechnology start-ups. 

The European pharma sector is looking to maintain supplies of essential medicines to Ukraine and Russia as invasion continues, while a US biopharma group is calling for industries to boycott all non-food and medical trade with Russia.

The European pharma sector is looking to maintain supplies of essential medicines to Ukraine and Russia as invasion continues while a US biopharma group is calling for industry to boycott all non-food and medical trade with Russia.

Competition to bring new schizophrenia therapies to market is increasing, with the need to demonstrate side-effect improvements over existing drugs especially important.